Experienced in Metastatic Brain Tumor

Bing Lu

Guiyang, CN 
Experienced in Metastatic Brain Tumor
Guiyang, CN 
OverviewLocationsClinical Research

Overview

Bing Lu practices in Guiyang, China. Mr. Lu is rated as an Experienced expert by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Esophagitis, and Lung Adenocarcinoma.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Metastatic Brain Tumor.

Gender
Male

Locations

Guiyang, China
Other Locations
China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Tislelizumab+Cisplatin or Carboplatin+Pemetrexed, Cisplatin or Carboplatin+Pemetrexed
Study Phase: Phase 3

35 Total Publications

Pretreatment CT-Based Machine Learning Radiomics Model Predicts Response in Inoperable Stage III NSCLC Treated with Concurrent Radiochemotherapy Plus PD-1 Inhibitors.
Pretreatment CT-Based Machine Learning Radiomics Model Predicts Response in Inoperable Stage III NSCLC Treated with Concurrent Radiochemotherapy Plus PD-1 Inhibitors.
Journal: Technology in cancer research & treatment
Published: June 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lu's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile